Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

Olink Proteomics for Mechanism of Action Elucidation in AAV-based Gene Therapies for Neuromuscular Disorders

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Olink Proteomics for Mechanism of Action Elucidation in AAV-based Gene Therapies for Neuromuscular Disorders

Olink Proteomics for AAV Gene Therapy Mechanism of Action Studies

CELL & GENE | RNA | BIOLOGICS

High-Plex Proteomics for Definitive MoA Characterization

    How does Olink Target/Explore differ from traditional ELISA for MoA studies?

    A: Olink’s Proximity Extension Assay (PEA) technology enables the simultaneous quantification of hundreds to thousands of proteins from a minimal sample volume (as little as 1µL). This high-plex capability provides a comprehensive view of biological pathways, unlike single-analyte ELISA, which is resource-intensive for broad screening.

    What sample matrices are compatible with Olink assays for AAV programs?

    A: Our bioanalytical laboratory routinely processes a wide range of matrices for Olink analysis, including serum, plasma, cerebrospinal fluid (CSF), and tissue lysates. This flexibility is suited for assessing both systemic and tissue-specific responses to AAV-based gene therapies.

    How does proteomics data support non-target tissue biodistribution analysis?

    A: Proteomics provides functional data that complements vector biodistribution studies. By identifying protein expression changes in tissues with low or undetectable vector presence, we can assess potential downstream biological effects and identify safety signals that qPCR or histology alone might not capture.

    What is the typical turnaround time for an Olink Explore study?

    A: Timelines are project-dependent and are influenced by sample cohort size and the required depth of bioinformatic analysis. Following sample receipt and QC, data acquisition and delivery of a top-line analysis report are typically completed within several weeks.

High-plex proteomics is an integral tool for defining the mechanism of action (MoA) of AAV-based gene therapies for neuromuscular disorders. Moving beyond simple transgene expression quantification, Olink platforms map the complex downstream proteomic shifts that define therapeutic effect and inform safety assessments. This approach generates robust, systems-level biological data to support regulatory submissions and de-risk clinical development.

Beyond Transgene Expression: Mapping the Proteomic Response

Confirming successful AAV delivery and transgene expression is only the first step. The central challenge is to demonstrate a comprehensive understanding of the resulting biological cascade. High-throughput proteomic screening provides the necessary data to build a complete MoA profile, linking vector administration to functional therapeutic outcomes.

Franklin Biolabs utilizes Olink’s PEA technology to achieve this with high sensitivity and specificity from precious preclinical samples. This platform is particularly effective for neuromuscular programs where sample volumes, especially CSF, are limited. By profiling thousands of proteins simultaneously, we can:

  • Identify and validate pharmacodynamic biomarkers.

  • Map on-target and off-target pathway modulation.

  • Uncover novel mechanisms related to therapeutic efficacy.

  • Characterize the host immune response to the vector capsid and payload.

This strategy generates a robust biomarker dataset to support and accelerate clinical validation.

A marketing flyer for Franklin Biolabs detailing their immunogenicity services, including various assays and support for cell and gene therapy clinical trials.

A scientist in a sterile laboratory setting uses a multichannel pipette to transfer pink liquid into a multi-well plate for a high-throughput experiment.

Optimizing Vector Specificity with Proteomic Data

Proteomic data provides direct functional evidence to guide AAV vector engineering and selection. For instance, development programs focused on increasing the specificity of AAV-based constructs benefit from deep proteomic analysis to confirm that refined targeting strategies successfully limit downstream biological changes in non-target tissues (PMID: 33359790). This analysis validates the intended MoA and builds a stronger safety case.

Similarly, when evaluating different AAV capsids for a specific application, such as liver-directed gene therapy, proteomic profiling offers a more complete picture than transduction efficiency alone. Comparative analysis of vectors like AAV3B and AAV8 can reveal distinct biological pathway activation profiles, informing capsid selection based on an optimized efficacy and safety signature (PMID: 26412589).

])

A GxP Framework for Biomarker Validation

Exploratory proteomics generates a wealth of potential biomarker candidates that must be validated within a structured, GxP-compliant framework to support an Investigational New Drug (IND) application. Our bioanalytical services are performed within a >100,000 sq ft facility designed to support programs from discovery through IND submission.

This infrastructure, combined with our deep regulatory experience, supports an 18-24 month IND timeline. Since 2019, programs managed by our core scientific leadership have achieved a 100% IND success rate, a track record we continue at Franklin Biolabs, which launched in 2024.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities